Atossa Therapeutics director granted 10,000 RSUs

Cigler Tessa reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Cigler Tessa reported acquisition or exercise transactions in this Form 4 filing.

ATOSSA THERAPEUTICS, INC. director Tessa Cigler reported an equity award of 10,000 shares of Common Stock on May 12, 2026. The award is structured as restricted stock units (RSUs), with each RSU representing a contingent right to receive one share of Common Stock.

The RSUs vest on the first anniversary of May 12, 2026, meaning they become deliverable as shares after that date if vesting conditions are satisfied. Following this grant, Cigler is shown as directly holding 10,000 shares of Common Stock.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Cigler Tessa

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 10,000 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.

Key Figures

RSUs granted: 10,000 shares Grant price: $0.0000 per share Holdings after transaction: 10,000 shares +1 more

4 metrics

RSUs granted 10,000 shares Restricted stock units representing Common Stock

Grant price $0.0000 per share Stated transaction price for RSU grant

Holdings after transaction 10,000 shares Total Common Stock directly held by Tessa Cigler

Vesting date First anniversary of May 12, 2026 RSUs vesting schedule for the 10,000-unit grant

Key Terms

restricted stock units ("RSUs"), contingent right, Common Stock

3 terms

restricted stock units ("RSUs") financial

"Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Common Stock financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ATOS director Tessa Cigler report?

Director Tessa Cigler reported an acquisition of 10,000 shares of Atossa Therapeutics Common Stock. The filing classifies this as a grant or award, recorded at a price of $0.0000 per share, rather than an open-market purchase.

How many RSUs did Tessa Cigler receive from Atossa Therapeutics (ATOS)?

Tessa Cigler received 10,000 restricted stock units (RSUs) tied to Atossa Therapeutics Common Stock. Each RSU represents a contingent right to receive one share, so the full grant corresponds to 10,000 potential shares upon vesting.

When do Tessa Cigler’s Atossa Therapeutics RSUs vest?

The RSUs granted to Tessa Cigler vest on the first anniversary of May 12, 2026. Vesting on that date means the contingent right associated with each RSU can convert into one share of Atossa Therapeutics Common Stock, subject to the award’s conditions.

Is Cigler’s ATOS Form 4 transaction an open-market stock purchase?

No, the transaction is reported with code A as a grant, award, or other acquisition. It reflects 10,000 RSUs awarded at a stated price of $0.0000 per share, not a cash purchase on the open market.

What are Tessa Cigler’s reported ATOS holdings after this RSU grant?

After the reported transaction, Tessa Cigler’s total direct holdings are shown as 10,000 shares of Atossa Therapeutics Common Stock. This figure reflects the position following the grant recorded in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:24 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cigler Tessa

(Last) (First) (Middle)

C/O ATOSSA THERAPEUTICS, INC.

1448 NW MARKET STREET SUITE 500

(Street)

SEATTLE WASHINGTON 98107

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ATOSSA THERAPEUTICS, INC. [ ATOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		A		10,000(1)	A	$0	10,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.

	Tessa Cigler	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)